{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:31:35Z","timestamp":1786480295208,"version":"build-2736575974"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"DOI":"10.13039\/100007923","name":"University of Wisconsin Carbone Cancer Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007923","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008028","name":"University of Wisconsin School of Medicine and Public Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008028","id-type":"DOI","asserted-by":"crossref"}]},{"name":"University of Wisconsin Health"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>\n                    Cytomegalovirus (CMV) and BK virus (BKV) are common viral infections after kidney transplant. Their negative effects on patient and graft outcomes have been well described. However, despite improvement in screening and prophylaxis strategies, CMV and BKV continue to negatively affect both short- and long-term graft survival. Adequate cell-mediated immunity is essential for the control and prevention of opportunistic viral infections, such as CMV and BKV. Therefore, immune reconstitution, in particular T cell recovery, is a key factor in antiviral control after kidney transplantation. Cell-based immunotherapy offers an attractive alternative approach to traditional interventions. Adoptive T cell transfer,\n                    <jats:italic toggle=\"yes\">via<\/jats:italic>\n                    infusions of allogeneic virus-specific T lymphocytes is capable of restoring virus-specific T cell immunity, and are safe and effective in the treatment of viral infections after hematopoietic stem cell transplantation. In this article, we review the emerging role of virus-specific T cell therapy in the management of CMV and BKV after kidney transplantation. On the basis of the available data, virus-specific T cell therapy may be a promising addition to the antiviral treatment armamentarium after kidney transplantation. Future studies are needed to more clearly define the efficacy and risks of virus-specific T cell therapy in the kidney transplant population.\n                  <\/jats:p>","DOI":"10.34067\/kid.0001572021","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T16:40:16Z","timestamp":1616776816000},"page":"905-915","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Role of Virus-Specific T Cell Therapy for Cytomegalovirus and BK Infections in Kidney Transplant Recipients"],"prefix":"10.34067","volume":"2","clinical-trial-number":[{"clinical-trial-number":"nct04294472","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1667-7465","authenticated-orcid":false,"given":"Sandesh","family":"Parajuli","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Jorgenson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross O.","family":"Meyers","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Professional Development, University of Wisconsin-Madison School of Pharmacy, Madison, Wisconsin"},{"name":"Program for Advanced Cell Therapy, University of Wisconsin Hospital and Clinics and School of Medicine and Public Health, Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjang","family":"Djamali","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Galipeau","sequence":"additional","affiliation":[{"name":"Program for Advanced Cell Therapy, University of Wisconsin Hospital and Clinics and School of Medicine and Public Health, Madison Wisconsin"},{"name":"Division of Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"},{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"key":"B1-20250825","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri1526","article-title":"Cellular immunotherapy for viral infection after HSC transplantation","volume":"5","author":"Moss","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B2-20250825","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJM199806113382407","article-title":"Infection in organ-transplant recipients","volume":"338","author":"Fishman","year":"1998","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"B3-20250825","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.2215\/CJN.02900707","article-title":"Viral infection after renal transplantation: Surveillance and management","volume":"3","author":"Weikert","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B4-20250825","first-page":"245","article-title":"BK virus-associated nephropathy in kidney transplant recipients","volume":"10","author":"Garces","year":"2010","journal-title":"Ochsner J"},{"key":"B5-20250825","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00430-007-0066-x","article-title":"The history of cytomegalovirus and its diseases","volume":"197","author":"Ho","year":"2008","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1681\/ASN.2004121113","article-title":"Viral infection in the renal transplant recipient","volume":"16","author":"Kotton","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1513\/pats.200507-073JS","article-title":"Transplant-related immunosuppression: A review of immunosuppression and pulmonary infections","volume":"2","author":"Duncan","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"B8-20250825","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N Engl J Med"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"e13189","DOI":"10.1111\/tid.13189","article-title":"The impact of recurrent cytomegalovirus infection on long-term survival in solid organ transplant recipients","volume":"21","author":"Gardiner","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"B10-20250825","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/j.1600-6143.2010.03114.x","article-title":"Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients","volume":"10","author":"Asberg","year":"2010","journal-title":"Am J Transplant"},{"key":"B11-20250825","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"B12-20250825","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1517\/14656561003742954","article-title":"Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients","volume":"11","author":"Asberg","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"B13-20250825","doi-asserted-by":"crossref","first-page":"e5512","DOI":"10.1371\/journal.pone.0005512","article-title":"Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy","volume":"4","author":"Kalil","year":"2009","journal-title":"PLoS One"},{"key":"B14-20250825","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0140-6736(00)02350-3","article-title":"Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation","volume":"355","author":"Emery","year":"2000","journal-title":"Lancet"},{"key":"B15-20250825","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ajt.15183","article-title":"Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis","volume":"19","author":"Leeaphorn","year":"2019","journal-title":"Am J Transplant"},{"key":"B16-20250825","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/tid.12537","article-title":"Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: A single-center retrospective cohort study","volume":"18","author":"Young","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"B17-20250825","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/phar.1987","article-title":"Ganciclovir-resistant cytomegalovirus infection in abdominal solid organ transplant recipients: Case series and review of the literature","volume":"37","author":"Rolling","year":"2017","journal-title":"Pharmacotherapy"},{"key":"B18-20250825","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"B19-20250825","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: A randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston","year":"2012","journal-title":"Am J Transplant"},{"key":"B20-20250825","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: A randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B21-20250825","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in\u00a0vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B22-20250825","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: An evidence-based review","volume":"12","author":"El Helou","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"Suppl 4","key":"B23-20250825","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/ajt.12110","article-title":"AST Infectious Diseases Community of Practice: BK polyomavirus in solid organ transplantation","volume":"13","author":"Hirsch","year":"2013","journal-title":"Am J Transplant"},{"key":"B24-20250825","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/j.1523-1755.2005.00602.x","article-title":"BK virus nephritis: Risk factors, timing, and outcome in renal transplant recipients","volume":"68","author":"Vasudev","year":"2005","journal-title":"Kidney Int"},{"key":"B25-20250825","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/00007890-200104150-00013","article-title":"Polyoma virus infection after renal transplantation. Use of immunostaining as a guide to diagnosis","volume":"71","author":"Ahuja","year":"2001","journal-title":"Transplantation"},{"key":"B26-20250825","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.tp.0000269706.59977.a5","article-title":"Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: A prospective evaluation","volume":"84","author":"Drachenberg","year":"2007","journal-title":"Transplantation"},{"key":"B27-20250825","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12817","article-title":"Impact of low-level BK polyomavirus viremia on intermediate-term renal allograft function","volume":"20","author":"Korth","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"B28-20250825","doi-asserted-by":"crossref","first-page":"e13216","DOI":"10.1111\/ctr.13216","article-title":"Which is more nephrotoxic for kidney transplants: BK nephropathy or rejection?","volume":"32","author":"Parajuli","year":"2018","journal-title":"Clin Transplant"},{"key":"B29-20250825","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.TP.0000156165.83160.09","article-title":"Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations","volume":"79","author":"Hirsch","year":"2005","journal-title":"Transplantation"},{"key":"B30-20250825","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1399-3062.2006.00166.x","article-title":"Polyomavirus-associated nephropathy: Update of clinical management in kidney transplant patients","volume":"8","author":"Trofe","year":"2006","journal-title":"Transpl Infect Dis"},{"key":"B31-20250825","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1097\/TP.0b013e3182921995","article-title":"Risk factors for BK virus infection in the era of therapeutic drug monitoring","volume":"95","author":"Borni-Duval","year":"2013","journal-title":"Transplantation"},{"key":"B32-20250825","doi-asserted-by":"crossref","first-page":"e13528","DOI":"10.1111\/ctr.13528","article-title":"AST Infectious Diseases Community of Practice: BK polyomavirus in solid organ transplantation-guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Hirsch","year":"2019","journal-title":"Clin Transplant"},{"issue":"Suppl 4","key":"B33-20250825","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1111\/j.1600-6143.2009.02904.x","article-title":"AST Infectious Diseases Community of Practice: BK virus in solid organ transplant recipients","volume":"9","author":"Hirsch","year":"2009","journal-title":"Am J Transplant"},{"key":"B34-20250825","doi-asserted-by":"crossref","first-page":"e13561","DOI":"10.1111\/tid.13561","article-title":"Risk factors for progression from low level BK dnaemia to unfavorable outcomes after BK management via immunosuppressive reduction [published online ahead of print January 5, 2021]","author":"Kharel","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B35-20250825","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1097\/TP.0000000000001698","article-title":"Clinical-scale rapid autologous BK virus-specific T cell line generation from kidney transplant recipients with active viremia for adoptive immunotherapy","volume":"101","author":"Lamarche","year":"2017","journal-title":"Transplantation"},{"key":"B36-20250825","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"key":"B37-20250825","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"B38-20250825","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","article-title":"Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines","volume":"362","author":"Peggs","year":"2003","journal-title":"Lancet"},{"key":"B39-20250825","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"B40-20250825","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1046-2023(03)00125-7","article-title":"Detection and enrichment of antigen-specific CD4+ and CD8+ T cells based on cytokine secretion","volume":"31","author":"Campbell","year":"2003","journal-title":"Methods"},{"key":"B41-20250825","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1002\/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.0.CO;2-C","article-title":"Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion","volume":"29","author":"Brosterhus","year":"1999","journal-title":"Eur J Immunol"},{"key":"B42-20250825","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12967-014-0336-5","article-title":"Rapid generation of clinical-grade antiviral T cells: Selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells","volume":"12","author":"Tischer","year":"2014","journal-title":"J Transl Med"},{"key":"B43-20250825","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/vox.12291","article-title":"Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: Results of a feasibility exercise","volume":"109","author":"Bunos","year":"2015","journal-title":"Vox Sang"},{"key":"B44-20250825","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3389\/fimmu.2016.00393","article-title":"Comparative analysis of clinical-scale IFN-\u03b3-Positive T-cell enrichment using partially and fully integrated platforms","volume":"7","author":"Priesner","year":"2016","journal-title":"Front Immunol"},{"key":"B45-20250825","first-page":"52808","article-title":"Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system","author":"Kumaresan","year":"2015","journal-title":"J Vis Exp"},{"key":"B46-20250825","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1172\/JCI90599","article-title":"Immunotherapy for transplantation-associated viral infections","volume":"127","author":"Roddie","year":"2017","journal-title":"J Clin Invest"},{"key":"B47-20250825","first-page":"278","article-title":"Adoptive T cell therapy for the treatment of viral infections","volume":"3","author":"Arasaratnam","year":"2015","journal-title":"Ann Transl Med"},{"key":"B48-20250825","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/ajt.13023","article-title":"Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient","volume":"15","author":"Macesic","year":"2015","journal-title":"Am J Transplant"},{"key":"B49-20250825","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet"},{"key":"B50-20250825","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/TXD.0000000000000557","article-title":"Epstein-barr virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: Pathogenesis, clinical manifestations, diagnosis, and management","volume":"2","author":"Nijland","year":"2015","journal-title":"Transplant Direct"},{"key":"B51-20250825","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.5","article-title":"Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation","volume":"4","author":"Holmes-Liew","year":"2015","journal-title":"Clin Transl Immunology"},{"key":"B52-20250825","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1586\/1744666X.2014.943190","article-title":"Immune-based monitoring for cytomegalovirus infection in solid organ transplantation: Is it ready for clinical primetime?","volume":"10","author":"Melendez","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"B53-20250825","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1073\/pnas.96.18.10391","article-title":"Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease","volume":"96","author":"Khanna","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B54-20250825","first-page":"5745","article-title":"Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients","volume":"4","author":"Nelson","year":"2020","journal-title":"Blood Adv"},{"key":"B55-20250825","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","article-title":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation","volume":"134","author":"Feuchtinger","year":"2006","journal-title":"Br J Haematol"},{"key":"B56-20250825","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"B57-20250825","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.5858\/2008-0679-RS.1","article-title":"Solid organ transplant-associated acute graft-versus-host disease","volume":"134","author":"Zhang","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"B58-20250825","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B59-20250825","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/bmt.2017.232","article-title":"Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT","volume":"53","author":"Qian","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B60-20250825","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood"},{"key":"B61-20250825","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1128\/CMR.13.1.83","article-title":"New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients","volume":"13","author":"Sia","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"B62-20250825","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00007890-198802000-00022","article-title":"The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients","volume":"45","author":"Lewis","year":"1988","journal-title":"Transplantation"},{"key":"B63-20250825","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1182\/blood-2009-07-230482","article-title":"Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)","volume":"114","author":"De Angelis","year":"2009","journal-title":"Blood"},{"key":"B64-20250825","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1182\/blood-2009-07-228387","article-title":"Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease","volume":"114","author":"Brewin","year":"2009","journal-title":"Blood"},{"key":"B66-20250825","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1097\/TXD.0000000000000641","article-title":"Clearance of BK virus nephropathy by combination antiviral therapy with intravenous immunoglobulin","volume":"3","author":"Kable","year":"2017","journal-title":"Transplant Direct"},{"key":"B67-20250825","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/ejh.12848","article-title":"BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation","volume":"98","author":"Pello","year":"2017","journal-title":"Eur J Haematol"},{"key":"B68-20250825","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"key":"B69-20250825","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1084\/jem.20040613","article-title":"Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers","volume":"202","author":"Cobbold","year":"2005","journal-title":"J Exp Med"},{"key":"B70-20250825","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood"},{"key":"B71-20250825","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwaite","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"B72-20250825","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2008-06-161695","article-title":"Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation","volume":"112","author":"Micklethwaite","year":"2008","journal-title":"Blood"},{"key":"B73-20250825","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/ciq042","article-title":"Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation","volume":"52","author":"Peggs","year":"2011","journal-title":"Clin Infect Dis"},{"key":"B74-20250825","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion"},{"key":"B75-20250825","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/CJI.0b013e31824300a2","article-title":"Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections","volume":"35","author":"Bao","year":"2012","journal-title":"J Immunother"},{"key":"B76-20250825","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/CJI.0b013e31826e35f6","article-title":"Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in\u00a0vitro-generated CMV pp65-specific CD8+ T-cell lines","volume":"35","author":"Meij","year":"2012","journal-title":"J Immunother"},{"key":"B77-20250825","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cid\/cis625","article-title":"Rapid salvage treatment with virus-specific T cells for therapy-resistant disease","volume":"55","author":"Uhlin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B78-20250825","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bbmt.2015.05.015","article-title":"Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia","volume":"21","author":"Koehne","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0001572021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:02:20Z","timestamp":1786478540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0001572021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0001572021","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"2021-03-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}